Their approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using their proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.